biodyne

What biodyne does

Biodyne Co., Ltd. is a South Korean medical device company founded in 2009 and headquartered in Seoul that develops and manufactures liquid-based cytology (LBC) equipment and reagent consumables for cancer diagnosis. The company's core technology, Blowing Technology, is a proprietary sample-processing method first patented in Korea in 2011, with subsequent patents granted in the USA (apparatus in 2017, method in 2021), Japan, China, Russia, India, and 22 countries in total. The technology underpins the PATHPLORER LBC System family of automated slide processing instruments (PATHPLORER AUTO, PLUS 4.63, PLUS 4.7, and ECO variants) and the PATHPLORER LBC Solution cell preservation and fixation reagents, which together are claimed to deliver 3x faster inspection speed and higher diagnostic accuracy than conventional cytology methods.

Biodyne's revenue model is anchored on B2B medical device sales to hospitals, diagnostic centers, and cytology laboratories, with a recurring consumables stream from reagent kits and the upcoming EarlyPap self-collection brush for cervical cancer screening. The company generates revenue through direct sales backed by an ARS customer service operation and through overseas healthcare partner contracts; exports reach 20+ countries across East Asia, Southeast Asia, North America, Europe, and South Asia. The technology has been licensed to Roche for use in the VENTANA SP 400 diagnostic instrument platform, publicly demonstrated in Japan in 2025, providing tier-1 OEM validation. The company completed a KOSDAQ IPO in March 2021, raising approximately 23.2 billion KRW through issuance of 1,030,000 new shares, and reported 2022 revenue of 122 billion KRW, up from 36 billion KRW in 2020.

The customer base is diversified across hospitals, medical centers, and cytology laboratories globally, with named institutional customers including Chung-Ang University-affiliated programs and Chungbuk National University Hospital in Korea. Geographic footprint is being extended with a Vietnam manufacturing facility in Hung Yen province, groundbreaking March 27, 2026, with the first phase dedicated to EarlyPap production and the second phase planned for non-gynecological product lines. The company participates in South Korea's Ministry of Science and ICT Brainpool program for foreign scientist recruitment and maintains a research partnership with Chung-Ang University. Awards include the 2023 Proud Small Business Owner recognition and the 2025 ICC Best e-Poster award for the Earlypap Brush in Florence, Italy.

Name

biodyne

Legal name

(주)바이오다인 (Biodyne Co., Ltd.)

Website

https://biodyne.asia

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Biodyne Co., Ltd. is a South Korean medical device company that develops liquid-based cytology equipment and reagents for cancer diagnosis. Its proprietary Blowing Technology powers the PATHPLORER LBC System and is licensed to Roche for the VENTANA SP 400 platform.

Ownership category

akta.pro rank

Product category

Cancer Diagnostic Medical Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Analytical Instruments & Chromatography Systems (HLAGAIAA)

Keywords

• Liquid-based cytology
• Cancer diagnostic equipment
• Medical device manufacturing
• Cervical cancer screening
• Diagnostic reagents

Headquarters

HQ city

Fort Wayne

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Infrastructure, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Medical Device Equipment Sales: Sale of PATHPLORER LBC System instruments to hospitals, diagnostic centers, and laboratories. Equipment includes automated slide processing systems available in multiple models.
2. Diagnostic Reagent Kits: Sale of liquid-based cytology solutions and reagents including PATHPLORER LBC Solution, PATHPLORER Lysis Solution, and related consumables for the cell sample processing workflow.
3. Consumables and Supplies: Ongoing sales of consumable products including EarlyPap brushes for self-collection and other single-use diagnostic materials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Biodyne develops and manufactures liquid-based cytology (LBC) cancer diagnostic equipment and reagent kits powered by its proprietary "Blowing Technology." The portfolio includes the PATHPLORER LBC System (automated slide specimen processing equipment available in AUTO, PLUS 4.63, PLUS 4.7, and ECO variants) and the PATHPLORER LBC Solution (cell preservation and fixation reagents). The company is also preparing to launch EarlyPap, a self-collection kit for cervical cancer screening, and has licensed its core technology to Roche for the VENTANA SP 400 diagnostic platform.

Product overview

Biodyne offers a unified portfolio of cancer diagnostic products centered on liquid-based cytology (LBC) technology. The core offerings include PATHPLORER LBC Solution (cell preservation and fixation reagents) and PATHPLORER LBC System (slide specimen processing equipment), available in multiple variants: PATHPLORER AUTO (automated), PATHPLORER PLUS 4.63/4.7, and PATHPLORER ECO. The company also produces Earlypap, a self-collection kit for cervical cancer screening. Additionally, Biodyne's technology has been licensed to Roche for the VENTANA SP 400 equipment. All products focus on early cancer detection through cell-based diagnostic methods.

Differentiator

Problem solved

Functional benefit

Brands

• PATHPLORER LBC System: Liquid-based cytology slide specimen processing equipment for cancer diagnosis, including models PATHPLORER AUTO, PATHPLORER PLUS 4.63, PATHPLORER PLUS 4.7, and PATHPLORER ECO.
• PATHPLORER LBC Solution
• EarlyPap
• VENTANA SP 400
• Cellprep

Products and services

• PATHPLORER LBC System

Quantifiable outcome

• 3x faster inspection speed with higher accuracy compared to conventional methods
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Roche (Switzerland)coreOEM/ Whitelabel/ Licensing PartnerRoche developed VENTANA SP 400 equipment based on Biodyne's technology, demonstrating international validation of Biodyne's core liquid-based cytology technology. This is a significant technology licensing partnership where Biodyne's proprietary Blowing Technology is embedded into Roche's diagnostic equipment platform. The partnership was publicly announced at a Japanese exhibition in 2025.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Hologic: Developer of ThinPrep, the dominant liquid-based cytology system globally. Hologic is Biodyne's primary direct competitor in LBC equipment and reagents for cervical and non-gynecological cytology, with a much larger installed base and commercial footprint.
• BD (Becton, Dickinson and Company): Through its BD Diagnostics segment, BD offers SurePath, a major LBC consumables and instrumentation platform competing head-to-head with Biodyne's PATHPLORER in cytology labs and cervical cancer screening programs worldwide.

Broad incumbents

• Roche Diagnostics: Operates the VENTANA tissue diagnostics franchise, which includes the SP 400 instrument co-developed with Biodyne. Roche is both a licensing partner and a broad incumbent in anatomic pathology and cancer diagnostics, and could expand into adjacent cytology areas.
• Danaher (Beckman Coulter, Leica Biosystems, Cepheid): Through its diagnostics and life-sciences subsidiaries (notably Leica Biosystems in anatomic pathology), Danaher competes broadly in cancer diagnostics instrumentation and consumables, overlapping with Biodyne's hospital/lab cytology channel.
• Fujirebio (H.U. Group Holdings): Specializes in in-vitro diagnostics including oncology and women's health screening assays (e.g., cervical cancer biomarkers). Comparable as a broader incumbent in cancer diagnostics reagents and instruments with overlapping cervical screening end markets.

Emerging players

• Guangzhou Anjie Biomedical Technology: Chinese manufacturer of liquid-based cytology systems and reagents serving hospitals and pathology labs in Asia. Comparable to Biodyne as an emerging LBC-focused player expanding outside its home market with cost-competitive offerings.
• SEAL Biosciences: Emerging diagnostics company developing molecular and cellular assays including cytology-adjacent tools for cancer screening. Comparable as a niche, technology-led player pursuing early-cancer-detection workflows relevant to Biodyne's LBC and EarlyPap franchises.

Regional players

• Yantai Hede Biotechnology: China-based developer of cytology diagnostics solutions including LBC consumables. A regional peer with overlapping cervical cancer screening product focus, primarily serving the China market rather than competing directly in Korea or the U.S.
• CellPath (CellPath plc): UK-based supplier of consumables, instruments and services to the cellular pathology market, including cytology and histology products. Comparable as a mid-sized player serving pathology and cytology labs with both instrumentation and consumables.

Others

• Sekisui Diagnostics: Developer and manufacturer of clinical chemistry and immunoassay diagnostics, including cytology-adjacent reagents. Comparable as a diagnostics ecosystem participant whose channels, reagents, and lab relationships overlap with Biodyne's hospital/lab customer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/biodyneusa
• LinkedInlinkedin.com/company/biodyne-usa

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about biodyne